Norfloxacin versus nalidixic acid in the treatment of urinary tract infections.
Norfloxacin (MK-0366), a new oral quinoline antimicrobial agent, was shown to have much wider spectrum than nalidixic acid which includes Pseudomonas aeruginosa and gram-positive cocci. Many studies have been undertaken to determine the clinical effectiveness of norfloxacin in patients with urinary tract infections. Seventy-two patients with urinary tract infections caused by sensitivity strains were treated with either 400 mg norfloxacin per 12 hours or nalidixic acid 500 mg every 8 hours for 7 days. Follow-up examinations showed that norfloxacin is more effective than nalidixic acid, 93% and 83%, respectively, for the eradication of bacteriuria and symptoms. Adverse reactions due to norfloxacin were fewer and minor, and the tolerability seemed to be better than that of nalidixic acid.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy; D001437:Bacteriuria / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009268:Nalidixic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D009643:Norfloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D011897:Random Allocation; D012008:Recurrence; D014552:Urinary Tract Infections / Q000188:drug therapy*
D009268:Nalidixic Acid; D009643:Norfloxacin